Glucagon receptor of human liver. Studies of its molecular weight and binding properties, and its ability to activate hepatic adenylyl cyclase of non-obese and obese subjects
- PMID: 2982913
- PMCID: PMC423504
- DOI: 10.1172/JCI111713
Glucagon receptor of human liver. Studies of its molecular weight and binding properties, and its ability to activate hepatic adenylyl cyclase of non-obese and obese subjects
Abstract
The glucagon receptor and the adenylyl cyclase system of human liver membranes were studied in six non-obese and six obese subjects who had elevated insulin and plasma glucagon levels. Analysis of specific glucagon binding by the method of Scatchard demonstrated a linear (monocomponent) plot with a dissociation constant of 2-3 nM, and the binding at low hormone concentrations was sensitive to guanosine triphosphate (GTP). The molecular weight of the glucagon receptor was 63,000 D as determined by an affinity labeling procedure and sodium dodecyl sulfate gel electrophoresis. Affinity labeling of this structure was specific for glucagon and inhibited by GTP. Glucagon stimulated the production of cyclic adenosine monophosphate (cAMP) by human membranes with half-maximal activation elicited by 6 nM hormone. The human cyclase system required GTP to facilitate an optimal glucagon response. NaF (10 mM) also activated the cyclase system and produced the same magnitude of response as maximum glucagon activation. A comparison of the liver adenylyl cyclase system of non-obese and obese subjects was made using glucagon (5 nM and 1 microM) and NaF (10 mM). No significant differences in cAMP production were noted between the two groups, regardless of the agent used to activate the enzyme. These findings agree with the glucagon binding studies that showed similar amounts of binding activity in the membranes from the two groups. Also, there was no influence of either age or sex of the subjects on the adenylyl cyclase response. In conclusion, human liver membranes contain a glucagon receptor and an adenylyl cyclase system that correspond closely to the well-studied system in animal liver. This system in human obesity is not altered by the approximately twofold elevation in plasma glucagon that occurs in this metabolic disorder.
Similar articles
-
Glucagon-stimulable adenylyl cyclase in rat liver. Effects of chronic uremia and intermittent glucagon administration.J Clin Invest. 1984 Apr;73(4):1004-12. doi: 10.1172/JCI111285. J Clin Invest. 1984. PMID: 6323531 Free PMC article.
-
Characterization of glucagon receptors in Golgi fractions of rat liver: evidence for receptors that are uncoupled from adenylyl cyclase.Biochemistry. 1986 May 6;25(9):2612-20. doi: 10.1021/bi00357a050. Biochemistry. 1986. PMID: 3013309
-
Glucagon-stimulable adenylyl cyclase in rat liver. The impact of streptozotocin-induced diabetes mellitus.J Clin Invest. 1984 Apr;73(4):1013-23. doi: 10.1172/JCI111286. J Clin Invest. 1984. PMID: 6323532 Free PMC article.
-
Interactions polypeptide hormones with cell membrane specific receptors: studies with insulin and glucagon.Diabetologia. 1976 May;12(2):83-100. doi: 10.1007/BF00428972. Diabetologia. 1976. PMID: 178558 Review. No abstract available.
-
Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs.Mol Cell Biochem. 1982 Apr 16;44(1):49-64. doi: 10.1007/BF00573846. Mol Cell Biochem. 1982. PMID: 6283336 Review.
Cited by
-
Altered action of glucagon on human liver in type 2 (non-insulin-dependent) diabetes mellitus.Diabetologia. 1987 May;30(5):323-6. doi: 10.1007/BF00299025. Diabetologia. 1987. PMID: 3038642
-
Glucagon and Its Receptors in the Mammalian Heart.Int J Mol Sci. 2023 Aug 15;24(16):12829. doi: 10.3390/ijms241612829. Int J Mol Sci. 2023. PMID: 37629010 Free PMC article. Review.
-
Insulin-like stimulation of cardiac fuel metabolism by physiological levels of glucagon: involvement of PI3K but not cAMP.Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E155-61. doi: 10.1152/ajpendo.90228.2008. Epub 2008 May 20. Am J Physiol Endocrinol Metab. 2008. PMID: 18492769 Free PMC article.
-
Glucagon's Metabolic Action in Health and Disease.Compr Physiol. 2021 Apr 1;11(2):1759-1783. doi: 10.1002/cphy.c200013. Compr Physiol. 2021. PMID: 33792899 Free PMC article.
-
Glucagon, cyclic AMP, and hepatic glucose mobilization: A half-century of uncertainty.Physiol Rep. 2022 May;10(9):e15263. doi: 10.14814/phy2.15263. Physiol Rep. 2022. PMID: 35569125 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources